BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25157767)

  • 61. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
    Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
    J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
    Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K
    BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
    Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
    J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
    Edelman MJ; Otterson G; Leach J; Malpass T; Salgia R; Jones D; Mody TD; Govindan R
    J Thorac Oncol; 2011 Apr; 6(4):786-9. PubMed ID: 21289521
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
    BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Okamoto I; Nokihara H; Nomura S; Niho S; Sugawara S; Horinouchi H; Azuma K; Yoneshima Y; Murakami H; Hosomi Y; Atagi S; Ozaki T; Horiike A; Fujita Y; Okamoto H; Ando M; Yamamoto N; Ohe Y; Nakagawa K
    JAMA Oncol; 2020 May; 6(5):e196828. PubMed ID: 32163097
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
    Dy GK; Mandrekar SJ; Nelson GD; Meyers JP; Adjei AA; Ross HJ; Ansari RH; Lyss AP; Stella PJ; Schild SE; Molina JR; Adjei AA
    J Thorac Oncol; 2013 Jan; 8(1):79-88. PubMed ID: 23232491
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
    Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
    Clément-Duchêne C; Krupitskaya Y; Ganjoo K; Lavori P; McMillan A; Kumar A; Zhao G; Padda S; Zhou L; Pedro-Salcedo MS; Colevas AD; Wakelee HA
    J Thorac Oncol; 2010 Nov; 5(11):1821-5. PubMed ID: 20881641
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
    Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A
    J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.